Oncologic Benefits of Neoadjuvant Treatment versus Upfront Surgery in Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis

Oncologic Benefits of Neoadjuvant Treatment versus Upfront Surgery in Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis

Neoadjuvant treatment (NAT) followed by surgery is the primary treatment for borderline resectable pancreatic cancer (BRPC). However, there is limited high-level evidence supporting the efficacy of NAT in BRPC. PubMed was searched to identify studies that compared the survival between BRPC patients...

Full description

Bibliographic Details
Main Authors: Hye-Sol Jung, Hyeong Seok Kim, Jae Seung Kang, Yoon Hyung Kang, Hee Ju Sohn, Yoonhyeong Byun, Youngmin Han, Won-Gun Yun, Young Jae Cho, Mirang Lee, Wooil Kwon, Jin-Young Jang
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Cancers
Subjects:
meta-analysis
pancreatic cancer
borderline resectable
neoadjuvant
prognosis
Online Access:https://www.mdpi.com/2072-6694/14/18/4360

Internet

https://www.mdpi.com/2072-6694/14/18/4360

Similar Items